1200x628 Pacylex

Pacylex is developing a first-in-class, oral drug, PCLX-001, to selectively kill various types of cancer cells, while leaving normal cells unharmed. Animal tests show this drug candidate completely eliminates tumors in xenograft models of leukemias and lymphomas (AML, BL, DLBCL). Phase 1 clinical trial at three Canadian sites focusing on DLBCL and solid tumour patients are scheduled to begin in Q2, 2021.

2020 HIGHLIGHTS:

  • Completed 28-day, Investigational New Drug (IND)-enabling animal safety studies in two animal models
  • Created clinical trial consortium to carry out Phase 1 studies with Cross Cancer Institute (Edmonton), Princess Margaret Cancer Center (Toronto), and BC Cancer Agency (Vancouver)
  • Recruited two Key Opinion Leaders (KOL), experienced clinical researchers at MD Anderson Cancer Center in Houston TX are going to be
    drafting a protocol for treating patients with Acute Myelogenous Leukemia (AML) with PCLX-001.
  • Participated in/presented two posters at AACR, one poster at ASCO, JP Morgan Biotech Showcase and BIO2020
  • Participated in Creative Destruction Labs West
  • Agreed to terms with the University of Alberta to purchase patents
  • Funding raised in 2020: $3.8 million USD convertible note

TEC EDMONTON’S INFLUENCE:

  • Merck Invention Accelerator

“The most substantial benefit from the Merck accelerator has been the interaction with Merck pharmaceutical development experts at crucial development milestones. Being able to discuss results and decisions with big pharma experts and bring their perspectives to interpreting data and deciding next steps has been very valuable. Some of their development suggestions have contradicted our preliminary plan allowing us to rethink
the next steps. The selection for the Merck accelerator has given Pacylex credibility and a degree of validation.”
– Michael Weickert, CEO, Pacylex Pharmaceuticals